CCG SCORECARD

NHS Airedale, Wharfedale And Craven CCG

Commissioner data with CCG plans in grey. CCGs are ranked out of 23 Yorkshire & Humber CCGs until Jun 17, out of 207 CCGs nationally until May 18 (reduced to 195 from June 18)

| RTT | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
|--|------------|--------|------------------|-----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|---|
| | <87% | | 92.3% | 92.0% | 91.4% | 92.1% | 93.0% | 92.9% | 92.6% | 89.6% | 89.2% | 88.2% | 88.3% | 88.5% | 88.6% | - |
| Patients on incomplete non-emergency pathways (yet to start | 87% to 92% | Ť | #N/A | | | | | | | | | | | | | 7 |
| reatment) waiting no more than 18 weeks from referral | >=92% | Rank | 7/23 | | | 61/207 | | 44/207 | 35/207 | 104/207 | 103/207 | 114/207 | 105/207 | 111/207 | 105/195 | |
| | >10 | | , | , | | | | 0 | , | , | | 0 | 0 | 0 | , | |
| Number of patients waiting more that 52 weeks on incomplete | 1 to 10 | 1 | | | | | | | | | | | | | | |
| pathways | 0 | Rank | 15/23 | | | | | 20/207 | 53/207 | 50/207 | 74/207 | 93/207 | 70/207 | 71/207 | 68/195 | |
| Diagnostic | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| | <6% | | 3.9% | 4.4% | 1.4% | 0.7% | 0.9% | 1.0% | 4.8% | 3.9% | 2.3% | 3.5% | 5.8% | 8.8% | 5.0% | |
| Percentage of patients waiting 6 weeks or more for a diagnostic test | 1% to 6% | | #N/A | | | | | | | | | | | | | |
| 15 key tests) | >=1% | Rank | 19/23 | | | 59/207 | | 113/207 | 193/207 | 186/207 | 176/207 | 182/207 | 178/207 | 184/207 | 170/195 | |
| | >=170 | Nank | | | | | | | | | | | | | | |
| Cancer Monthly | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| Maximum two-week wait for first outpatient appointment for patients | <88% | | 95.0% | 92.3% | 89.2% | 96.4% | 95.6% | 79.1% | 75.0% | 76.2% | 81.1% | 75.9% | 76.3% | 75.8% | 75.4% | |
| eferred urgently with suspected cancer by a GP | 88% to 93% | | #N/A | | | | | | | | | | | | | |
| | >=93% | Rank | 9/23 | | | 54/207 | | 203/207 | 207/207 | 205/207 | 204/207 | 204/207 | 187/207 | 192/207 | 170/195 | |
| Maximum two-week wait for first outpatient appointment for patients | <88% | 1 | 100.0% | 97.9% | 93.3% | 100.0% | 96.3% | 95.2% | 96.4% | 98.3% | 96.2% | 93.1% | 86.6% | 93.6% | 95.8% | |
| eferred urgently with breast symptoms (where cancer was not initially | 88% to 93% | | #N/A | | | | | | | | | | | | | |
| uspected) | >=93% | Rank | 1/23 | | | 5/207 | | 134/207 | 96/207 | 41/207 | 98/207 | 114/207 | 129/207 | 78/207 | 38/195 | |
| Maximum 31-day wait from diagnosis to first definitive treatment for all | <91% | | 98.8% | 100.0% | 100.0% | 98.5% | 100.0% | 96.8% | 96.9% | 100.0% | 98.4% | 98.8% | 100.0% | 98.8% | 99.0% | |
| ancers | 91% to 96% | | #N/A | | | | | | | | | | | | | |
| ancers | >=96% | Rank | 9/23 | | | 74/207 | | 148/207 | 156/207 | 3/207 | 76/207 | 54/207 | 6/207 | 57/207 | 33/195 | |
| Maximum 31-day wait for subsequent treatment where that treatment is | <89% | | 93.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.6% | 100.0% | 95.7% | 95.8% | 93.8% | 100.0% | / |
| urgery | 89% to 94% | | #N/A | | | | | | | | | | | | | 1 |
| urgery | >=94% | Rank | 18/23 | | | 18/207 | | 23/207 | 26/207 | 135/207 | 20/207 | 124/207 | 106/207 | 122/207 | 1/195 | |
| Maximum 31-day wait for subsequent treatment where the treatment is | <93% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | • |
| n anti-cancer drug regimen | 93% to 98% | | #N/A | | | | | | | | | | | | | |
| in anii-banber didy regimen | >=98% | Rank | 1/23 | | | 29/207 | | 32/207 | 34/207 | 30/207 | 34/207 | 35/207 | 34/207 | 33/207 | 1/195 | |
| Maximum 31-day wait for subsequent treatment where the treatment is | <89% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.3% | 100.0% | 100.0% | 100.0% | • • • • • • • • |
| a course of radiotherapy | 89% to 94% | | #N/A | | | | | | | | | | | | | |
| t course or radiomerapy | >=94% | Rank | 1/23 | | | 22/207 | | 28/207 | 31/207 | 22/207 | 23/207 | 186/207 | 29/207 | 28/207 | 1/195 | |
| Maximum 62 day wait from urgant CD referral to first definition | <80% | | 88.5% | 77.8% | 94.1% | 85.7% | 86.7% | 83.0% | 75.6% | 83.1% | 88.1% | 87.5% | 81.3% | 76.3% | 78.9% | 1 |
| Maximum 62-day wait from urgent GP referral to first definitive | 80% to 85% | | #N/A | | | | | | | | | | | | | V ~ |
| reatment for cancer | >=85% | Rank | 3/23 | | | 63/207 | | 99/207 | 185/207 | 84/207 | 45/207 | 78/207 | 121/207 | 148/207 | 114/195 | |
| Maximum 62 day wait from referral from an NUIC agreening | <85% | | 100.0% | 100.0% | 88.9% | 75.0% | 100.0% | 100.0% | 100.0% | 87.5% | 80.0% | 66.7% | 50.0% | | 100.0% | |
| Maximum 62-day wait from referral from an NHS screening service to | 85% to 90% | | #N/A | | | | | | | | | | | | | Ĭ |
| irst definitive treatment for all cancers | >=90% | Rank | 1/23 | | | 165/207 | | 17/207 | 20/207 | 116/207 | 144/207 | 180/207 | 172/207 | | 12/195 | |
| Agyimum 60 day wait for first definitive treatment following s | NA | | 66.7% | 100.0% | 80.0% | 100.0% | 100.0% | 80.0% | 66.7% | 100.0% | 80.0% | 100.0% | 80.0% | 80.0% | 50.0% | |
| Maximum 62-day wait for first definitive treatment following a | | 1 | #N/A | | | | | | | | | | | | | / |
| consultants decision to upgrade the priority of the patients (all cancers) | | Rank | #N/A | | | 10/207 | | 146/207 | 176/207 | 14/207 | 136/207 | 10/207 | 127/207 | 133/207 | 181/195 | • |
| Mixed Sex Accommodation | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| | >10 | | | | | | | | | | | | | | | |
| reaches of Mixed-Sex Accommodation | 1 to 10 | + | | | | | | | | | | | | | | |
| | 0 | Rank | 1/23 | | | | 14/207 | | 83/207 | 108/207 | 16/207 | 13/207 | 128/207 | 24/207 | 1/195 | |
| Mental Health | | IVALIK | 1/23 14-15 Q4 | 15-16 Q1 | 15-16 Q2 | 15-16 Q3 | | 16-17 Q1 | 16-17 Q2 | | | 17-18 Q1 | 17-18 Q2 | 17-18 Q3 | 18-19 Q1 | |
| mental nealth | | | 14-15 Q4 | 13-10 (2) | 13-10 Q2 | 10-10 43 | 13-16 Q4 | 10-17 41 | 10-17 QZ | 10-17 43 | 10-17 44 | 17-10 41 | 17-10 42 | 17-16 Q3 | 10-19 (4) | A |
| Care Programme Approach (CPA): Percentage of people under adult | <90% | | 96.8% | 96.4% | 98.0% | 98.1% | 100.0% | 97.9% | 100.0% | 100.0% | 100.0% | 100.0% | 97.6% | 100.0% | 100.0% | |
| mental illness specialities on CPA who were followed up within 7 days | 90% to 95% | Ī | 30.070 | 30.170 | | 30.170 | 100.070 | 31.070 | 100.070 | 100.070 | 100.070 | 100.070 | 01.070 | 100.070 | 100.070 | √ • |
| of discharge from psychiatric inpatient care during the period | >=95% | Rank | 19/23 | 12/23 | 7/23 | 8/23 | 1/23 | 10/23 | 1/23 | 1/23 | 1/23 | 6/207 | 81/207 | 12/207 | 1/195 | |
| | /-00/0 | IValik | 13/23 | 12/23 | 1/23 | 0/23 | 1/23 | 10/23 | 1/23 | 1/23 | 1/23 | 0/201 | 31/201 | 12/201 | 1/193 | |

| Dementia | | | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | Jul-18 | |
|---|---------------------|-------|---------|---------|---------|--------|---------|----------|---------|---------|---------|----------|----------|----------|---------|--|
| | <62% | | 78.2% | 78.0% | 78.4% | 77.5% | 78.6% | 78.2% | 77.5% | 77.3% | 76.9% | 75.7% | 75.4% | 76.0% | 77.5% | ~~~ |
| Dementia diagnosis rate | 62% to 67% | | | | | | | | | | | | | | | |
| | >=67% | Rank | - | - | - | 30/207 | | 28/207 | | | 28/207 | | 32/207 | 29/195 | | |
| IAPT Monthly | | | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | l. |
| | <70% | | 95.5% | 100.0% | 100.0% | 96.6% | 91.7% | 100.0% | 96.6% | 95.3% | 100.0% | 100.0% | 95.8% | 96.4% | 100.0% | |
| IAPT 6 Weeks First Treatment | 70% to 75% | | | 100.070 | 100.070 | 00.070 | 01.170 | 100.070 | 00.070 | 00.070 | 100.070 | 100.070 | 00.070 | 00.470 | 100.070 | V |
| | >=75% | Rank | 8/23 | | | | | | | | | | | | | |
| | <90% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.7% | 100.0% | 96.4% | 100.0% | 100.0% | 100.0% | \\\ |
| IAPT 18 Weeks First Treatment | 90% to 95% | | | | | | | | | | | | | | | · ¥ |
| | >=95% | Rank | 1/23 | | | | | | | | | | | | | |
| IAPT (Rolling 3 month) | | | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | |
| | <4.20% | | 4.0% | 4.6% | 4.6% | 4.6% | 4.1% | 3.8% | 3.8% | 4.7% | 4.6% | 4.7% | 3.5% | 3.6% | 3.3% | |
| IAPT Access (rolling 3 months) | | ļ | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | |
| | >=4.75% | Rank | | | | | | | | | | | | | | (According to the Control of the Con |
| LART Reserve and the facilities of the second beautiful. | <45% | - | 60.0% | 58.7% | 59.4% | 59.7% | 59.7% | 54.4% | 50.0% | 49.0% | 50.0% | 52.3% | 52.2% | 54.1% | 54.4% | |
| IAPT Recovery rate (rolling 3 months) | 45% to 50% | D. I | 0/00 | | | | | | | | | | | | | |
| Fault Intervention Developie 2 Week Weits (valling greater | >=50% | Rank | 2/23 | Aug 47 | Can 47 | 0-4.47 | Nev 47 | Dec 47 | lan 40 | Esh 40 | Man 40 | A 40 | May 40 | hun 40 | bil 40 | |
| Early Intervention Psychosis - 2 Week Waits (rolling quarter | <u> </u> | | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | Jul-18 | A |
| Forty intervention in payabosis 2 week weit (Polling guerter) | <45% | - | 66.7% | 63.6% | 65.0% | 55.6% | 66.7% | 70.6% | 69.2% | 80.0% | 75.0% | 77.8% | 57.1% | 53.3% | 41.7% | |
| Early intervention in psychosis - 2 week wait (Rolling quarter) | 45% to 50% >=50% | Rank | | | | | 144/207 | 133/207 | | | 124/207 | | 161/207 | 175/195 | | |
| Safe Environment and Protecting from Avoidable Harm | >=50% | Naiik | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| | | | Juli-17 | Jui-17 | Aug-17 | 3ep-17 | OCI-17 | NOV-17 | Dec-17 | Jaii-10 | ren-10 | IVIAI-10 | Apr-10 | IVIAY-10 | Juli-10 | * |
| Incidence of healthcare associated infection (HCAI) i) MRSA - Cases | >0 | | 0 | | | | | | | | | | | | 1 | \wedge |
| which have been assigned to the CCG following a Post Infection | | D | 4/00 | | | 40/007 | | 0.4/0.07 | 00/007 | 00/007 | | 00/007 | 0.4/0.07 | 00/007 | 454/405 | |
| Review | | Rank | 1/23 | _ | _ | 19/207 | _ | 34/207 | 30/207 | 28/207 | _ | 32/207 | 34/207 | 26/207 | 151/195 | |
| lasidanas of hashbases associated infection (LICAN) iii Quiri | >Ceiling | - | 1 | 2 | 0 | 2 | 2 | 0 | 3 | 100/00= | 0 | 3 | 20/225 | 4 | 2 | $ \wedge \wedge \wedge \rangle $ |
| Incidence of healthcare associated infection (HCAI) ii) C.difficile | <=Ceiling | Rank | 1/23 | | | 22/207 | | 202/207 | 122/207 | 186/207 | | 127/207 | 29/207 | 93/207 | 28/195 | · V V V |
| | Ceiling | 35 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | l . |

CCG SCORECARD

NHS Bradford Districts CCG

Commissioner data with CCG plans in grey. CCGs are ranked out of 23 Yorkshire & Humber CCGs until Jun 17, out of 207 CCGs nationally until May 18 (reduced to 195 from June 18)

| Commissioner data with CCG plans in grey. CCGs are ranked out of 2 | 3 Yorkshire & F | lumber C | CGs until . | lun 17, ou | t of 207 CC | CGs nation | ally until Ma | ay 18 (redu | iced to 195 | 5 from June | e 18) | | | | | |
|--|-----------------|----------|-------------|------------|-------------|------------|---------------|-------------|-------------|-------------|----------|----------|----------|----------|----------|--|
| RTT | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| Patients on incomplete non-emergency pathways (yet to start | <87% | | 89.7% | 89.5% | 87.3% | 92.8% | 93.0% | 93.2% | 92.8% | 81.7% | 80.2% | 77.1% | 77.3% | 78.4% | 77.9% | |
| treatment) waiting no more than 18 weeks from referral | 87% to 92% | | #N/A | | | | | | | | | | | | | - |
| arounding no more than to work non-retorial | >=92% | Rank | 15/23 | | | 38/207 | | 38/207 | 28/207 | 195/207 | 197/207 | 198/207 | 187/207 | 189/207 | 190/195 | - |
| Number of patients waiting more that 52 weeks on incomplete | >10 | | | | | | | | | | | | | 13 | 11 | |
| pathways | 1 to 10 | | | | ŭ | , v | Ŭ | | | Ŭ | i i | i i | i i | | | |
| · • | 0 | Rank | 1/23 | 1/23 | | | | 23/207 | 24/207 | 23/207 | 49/207 | 104/207 | 139/207 | 169/207 | 129/195 | |
| Diagnostic | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| Deventors of noticets weiting Councils or more for a discussion test | <6% | | 3.5% | 3.3% | 4.0% | 1.3% | 1.1% | 1.3% | 2.3% | 1.8% | 0.3% | 0.6% | 0.7% | 0.8% | 0.9% | ~ |
| Percentage of patients waiting 6 weeks or more for a diagnostic test | 1% to 6% | | #N/A | | | | | | | | | | | | | |
| (15 key tests) | >=1% | Rank | 17/23 | | | 121/207 | | 131/207 | 163/207 | 137/207 | 19/207 | 49/207 | 42/207 | 69/207 | 74/195 | |
| Cancer Monthly | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| <u> </u> | <88% | | 94.2% | 94.2% | 91.8% | 98.5% | 97.3% | 71.6% | 76.0% | 72.8% | 76.4% | 72.8% | 65.1% | 66.3% | 69.6% | |
| Maximum two-week wait for first outpatient appointment for patients | 88% to 93% | | #N/A | | | | | | | | | | | | | |
| referred urgently with suspected cancer by a GP | >=93% | Rank | 14/23 | | | 8/207 | | 206/207 | 206/207 | 206/207 | 206/207 | 207/207 | 194/207 | 194/207 | 193/195 | |
| Maximum two-week wait for first outpatient appointment for patients | <88% | | 100.0% | 100.0% | 100.0% | 100.0% | 91.7% | 92.3% | 91.7% | 100.0% | 86.7% | 94.1% | 93.8% | 84.2% | 94.1% | — |
| referred urgently with breast symptoms (where cancer was not initially | 88% to 93% | | #N/A | | | | | | | | | | | | | ~~ V |
| suspected) | >=93% | Rank | 1/23 | | | 7/207 | | 177/207 | 170/207 | 7/207 | 189/207 | 93/207 | 58/207 | 147/207 | 64/195 | |
| · | <91% | | 99.2% | 97.0% | 100.0% | 98.1% | 90.3% | 97.6% | 100.0% | 95.2% | 99.2% | 98.0% | 98.1% | 96.6 | 96.9% | \ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| Maximum 31-day wait from diagnosis to first definitive treatment for all | 91% to 96% | | #N/A | | | | | | | | | | | | | V |
| cancers | >=96% | Rank | 3/23 | | | 93/207 | | 107/207 | 10/207 | 153/207 | 51/207 | 99/207 | 75/207 | 152/207 | 130/195 | |
| Maximum 31-day wait for subsequent treatment where that treatment | <89% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.9% | 91.3% | 100.0% | 93.3% | 100.0% | 93.1% | 100.0% | 100.0% | · · · · · · · · · · · · · · · · · · · |
| · · · · · · · · · · · · · · · · · · · | 89% to 94% | | #N/A | | | | | | | | | | | | | VV |
| is surgery | >=94% | Rank | 1/23 | | | 21/207 | | 159/207 | 162/207 | 16/207 | 151/207 | 25/207 | 134/207 | 25/207 | 1/195 | |
| Maximum 31-day wait for subsequent treatment where the treatment | <93% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | • |
| is an anti-cancer drug regimen | 93% to 98% | | #N/A | | | | | | | | | | | | | |
| is an anti-cancer drug regimen | >=98% | Rank | 1/23 | | | 32/207 | | 35/207 | 37/207 | 33/207 | 37/207 | 38/207 | 37/207 | 30/207 | 1/195 | |
| Maximum 31-day wait for subsequent treatment where the treatment | <89% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.1% | 100.0% | 100.0% | 100.0% | · · · · · · · · · · · · · · · · · · · |
| is a course of radiotherapy | 89% to 94% | | #N/A | | | | | | | | | | | | | V |
| is a course of radiotherapy | >=94% | Rank | 1/23 | | | 24/207 | | 31/207 | 33/207 | 23/207 | 25/207 | 113/207 | 31/207 | 29/207 | 1/195 | - |
| Maximum 62-day wait from urgent GP referral to first definitive | <80% | | 77.8% | 79.1% | 83.3% | 84.4% | 41.7% | 72.4% | 81.3% | 73.2% | 69.6% | 79.3% | 77.8% | 69.2% | 58.4% | |
| treatment for cancer | 80% to 85% | | #N/A | | | | | | | | | | | | | ¥ |
| | >=85% | Rank | 19/23 | | | 85/207 | | 191/207 | 142/207 | 173/207 | 187/207 | 166/207 | 154/207 | 182/207 | 194/195 | |
| Maximum 62-day wait from referral from an NHS screening service to | <85% | _ | 100.0% | 100.0% | 100.0% | 100.0% | | 81.0% | 100.0% | 88.9% | 100.0% | 100.0% | 85.7% | 85.7% | 85.7% | |
| first definitive treatment for all cancers | 85% to 90% | | #N/A | | | | | | | | | | | | | |
| | >=90% | Rank | 1/23 | | | 29/207 | | 164/207 | 22/207 | 111/207 | 23/207 | 25/207 | 123/207 | 129/207 | 137/195 | |
| Maximum 62-day wait for first definitive treatment following a | NA | - | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% | 75.0% | 100.0% | 100.0% | 100.0% | 100.0% | 75.0% | 66.7% | 66.7% | |
| consultants decision to upgrade the priority of the patients (all | | Devel | #N/A | | | 400/007 | | 400/007 | 40/007 | 404/007 | 44/007 | 44/007 | 400/007 | 404/007 | 470/405 | ¥ |
| cancers) | | Rank | #N/A | | | 183/207 | 0 (15 | 162/207 | 12/207 | 191/207 | 11/207 | 11/207 | 138/207 | 164/207 | 172/195 | |
| Mixed Sex Accommodation | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | I+- |
| December of Missel Over Assessment of the | >10 | - | | | | | | | | | | | | | | \ |
| Breaches of Mixed-Sex Accommodation | 1 to 10 | - · | | | | | 47/005 | | 47/00- | 47/00- | 40/00= | 40/00= | 40/00= | 07/00- | 4/405 | |
| Montal Health | 0 | Rank | | 15 10 00 | 15 10 0 | 15 10 0 | 17/207 | 10.17.0 | 17/207 | 17/207 | 19/207 | 16/207 | 19/207 | 27/207 | 1/195 | |
| Mental Health | | | 14-15 Q4 | 15-16 Q1 | 15-16 Q2 | 15-16 Q3 | 15-16 Q4 | 16-17 Q1 | 16-17 Q2 | 16-17 Q3 | 16-17 Q4 | 17-18 Q1 | 17-18 Q2 | 17-18 Q3 | 18-19 Q1 | |
| Care Programme Approach (CPA): Percentage of people under adult | <90% | | 98.0% | 99.1% | 98.9% | 93.7% | 96.0% | 98.3% | 97.0% | 98.8% | 100.0% | 97.1% | 98.0% | 95.5% | 94.2% | |
| mental illness specialities on CPA who were followed up within 7 days | 90% to 95% | | 30.070 | 33.170 | 30.570 | 30.170 | 30.078 | 30.070 | 31.070 | 30.070 | 100.070 | 31.170 | 30.070 | 30.070 | 3 T.E 70 | V |
| of discharge from psychiatric inpatient care during the period | >=95% | Rank | 14/23 | 4/23 | 6/23 | 21/23 | 20/23 | 8/23 | 14/23 | 10/23 | 1/23 | 105/207 | 96/207 | 143/207 | | |
| 5 1-7 1 3- /F | >=30 /0 | IVALIA | 14/23 | 4/23 | 0/23 | 21/25 | 20/23 | 0/23 | 14/23 | 10/23 | 1/23 | 103/207 | 30/207 | 143/207 | | |

| Dementia | | | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | Jul-18 | |
|--|------------|------|--------|---------|---------|---------|---------|---------|--------|---------|---------|--------|--------|---------|--------|----------|
| | <62% | | 82.0% | 82.1% | 82.4% | 83.0% | 83.5% | 82.9% | 82.3% | 81.3% | 81.3% | 81.6% | 81.6% | 81.6% | 80.9% | |
| Dementia diagnosis rate | 62% to 67% | | | | | | | | | | | | | | | |
| | >=67% | Rank | | | | 13/207 | | 14/207 | | | 16/207 | | 15/207 | | | |
| IAPT Monthly | | | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | |
| | <70% | | 95.3% | 95.9% | 97.8% | 95.8% | 94.3% | 93.9% | 94.6% | 96.9% | 95.3% | 98.4% | 95.7% | 92.5% | 97.7% | \sim |
| IAPT 6 Weeks First Treatment | 70% to 75% | | | 30.570 | 37.070 | 30.070 | 34.070 | 30.370 | 34.070 | 30.370 | 30.070 | 30.470 | 30.170 | 32.070 | 31.170 | . • |
| | >=75% | Rank | 9/23 | | | | | | | | | | | | | |
| | <90% | | 100.0% | 100.0% | 100.0% | 97.9% | 98.1% | 98.0% | 98.2% | 98.4% | 100.0% | 100.0% | 97.9% | 98.1% | 100.0% | |
| IAPT 18 Weeks First Treatment | 90% to 95% | | | .00.070 | 100.070 | 007 | 00 | 00.070 | 00.270 | 00 | .00.070 | | 0.1070 | 00/0 | | ما صب |
| | >=95% | Rank | | | | | | | | | | | | | | |
| IAPT (Rolling 3 month) | | | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | |
| | <4.20% | | 3.8% | 4.1% | 4.0% | 3.9% | 3.6% | 3.5% | 4.0% | 4.1% | 3.9% | 3.6% | 3.5% | 3.5% | 3.5% | |
| IAPT Access (rolling 3 months) | | | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | |
| | >=4.75% | Rank | 14/23 | | | | | | | | | | | | | |
| | <45% | | 52.1% | 56.0% | 54.2% | 51.1% | 46.8% | 46.2% | 47.7% | 48.4% | 49.4% | 49.4% | 50.7% | 51.0% | 48.5% | ^ |
| IAPT Recovery rate (rolling 3 months) | 45% to 50% | | | | | | | | | | | | | | | |
| | >=50% | Rank | 11/23 | 11/23 | | | | | | | | | | | | |
| Early Intervention Psychosis - 2 Week Waits (rolling quarter) | | | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | Jul-18 | _ |
| | <45% | | 80.4% | 71.7% | 68.8% | 68.5% | 70.0% | 74.1% | 61.4% | 62.2% | 51.3% | 59.4% | 61.3% | 66.7% | 64.7% | |
| Early intervention in psychosis - 2 week wait (Rolling quarter) | 45% to 50% | | | | | | | | | , | | | | | | |
| | >=50% | Rank | | | | | 138/207 | 121/207 | | | 173/207 | | | | | |
| Safe Environment and Protecting from Avoidable Harm | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| Incidence of healthcare associated infection (HCAI) i) MRSA - Cases | >0 | | 0 | | 1 | 0 | | | | | | | 1 | 1 | | |
| which have been assigned to the CCG following a Post Infection | | | | | | | | | | | | | | | | <u> </u> |
| Review | | Rank | 19/23 | | | 199/207 | | | 33/207 | 31/207 | | 35/207 | 40/207 | 151/207 | 1/195 | |
| | >Ceiling | | 8 | 7 | 1 | 3 | 4 | 5 | 4 | 4 | 2 | 7 | 3 | 2 | 3 | \ _\ \ |
| Incidence of healthcare associated infection (HCAI) ii) C.difficile | <=Ceiling | Rank | 19/23 | | | 105/207 | | | 91/207 | 104/207 | | 49/207 | 69/207 | 43/207 | 53/195 | |
| 3.100 3.110aiii.10ai.0 a3333iai.0a ii.100ii.01 (1.10/ii.) ii) 3.110ii.01 | Ceiling | 115 | 8 | 10 | 14 | 9 | 8 | 8 | 9 | 9 | 9 | 11 | 10 | 9 | 10 | |

CCG SCORECARD

NHS Bradford City CCG
Commissioner data with CCG plans in grev. CCGs are ranked out of 23 Yorkshire & Humber CCGs until Jun 17, out of 207 CCGs nationally until May 18 (reduced to 195 from June 18)

| Commissioner data with CCG plans in grey. CCGs are ranked out of 23 | Yorkshire & Hu | ımber CC | CGs until Ju | ın 17, out | of 207 CCC | Gs national | ly until May | 18 (reduc | ed to 195 fi | rom June 1 | 8) | | | | | |
|--|---------------------|----------|-----------------|--------------|------------|-------------|--------------|-----------|--------------|-----------------|----------|----------|----------|----------|----------|--|
| RTT | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| Patients on incomplete non-emergency pathways (yet to start | <87% | | 88.7% | 87.7% | 88.8% | 90.5% | 92.0% | 91.8% | 91.9% | 81.6% | 81.0% | 76.7% | 75.8% | 75.9% | 74.9% | |
| reatment) waiting no more than 18 weeks from referral | 87% to 92% | | #N/A | | | | | | | | | | | | | |
| cament, waiting no more than to weeks nontrelenal | >=92% | Rank | 17/23 | | | 113/207 | | 84/207 | 51/207 | 196/207 | 195/207 | 199/207 | 193/207 | 194/207 | 194/195 | |
| lumber of patients waiting more that 52 weeks on incomplete | >10 | | | | | | | | | | | | | | | |
| athways | 1 to 10 | | | Ŭ | Ŭ | Ŭ | | | | · · | _ | _ | - | - | Ŭ | |
| aliways | 0 | Rank | 1/23 | | | | | 26/207 | 26/207 | 52/207 | 75/207 | 68/207 | 71/207 | 72/207 | 85/195 | |
| Diagnostic | | | Jan-17 | Feb-17 | Mar-17 | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Jan-00 | May-18 | Jun-18 | |
| | <6% | | 4.1% | 4.2% | 3.6% | 1.6% | 1.2% | 1.1% | 2.1% | 1.8% | 0.2% | 0.0% | 0.3% | 0.1% | 0.4% | - |
| Percentage of patients waiting 6 weeks or more for a diagnostic test | 1% to 6% | | #N/A | | | | | | | | | | | | | - |
| 15 key tests) | >=1% | Rank | 21/23 | | | 137/207 | | 120/207 | 152/207 | 138/207 | 6/207 | 1/207 | 6/207 | 1/207 | 17/195 | |
| Cancer Monthly | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| <u> </u> | <88% | | 94.7% | 96.6% | 93.9% | 90.5% | 100.0% | 68.3% | 80.7% | 71.5% | 77.5% | 75.0% | 70.4% | 66.4% | 76.4% | A |
| flaximum two-week wait for first outpatient appointment for patients | 88% to 93% | + | #N/A | #N/A | 33.370 | 30.370 | 100.078 | -00.570 | 00.170 | 11.570 | 11.570 | 13.070 | 70.770 | 00.470 | 10.470 | |
| eferred urgently with suspected cancer by a GP | >=93% | Rank | 15/23 | 5/23 | | | 1/207 | 207/207 | 204/207 | 207/207 | 205/207 | 205/207 | 193/207 | 193/207 | 188/195 | |
| Maximum two-week wait for first outpatient appointment for patients | >=93% <88% | INDIIN | 10/20 | 100.0% | | 100.0% | 100.0% | 100.0% | 207/201 | 100.0% | 200/201 | 200/201 | 100/201 | 100.0% | 50.0% | \ |
| eferred urgently with breast symptoms (where cancer was not initially | 88% to 93% | + | #N/A | #N/A | | 100.078 | 100.078 | 100.078 | | 100.078 | | | | 100.078 | 30.076 | V |
| uspected) | >=93% | Rank | TT 1 1/ / 1 | 1/23 | | | 8/207 | 6/207 | _ | 8/207 | | | | 1/207 | 182/195 | * |
| • | >=93% <91% | IVALIA | 100.0% | 100.0% | 100.0% | 96.8% | 100.0% | 88.2% | 86.7% | 100.0% | 88.9% | 100.0% | 94.1% | 93.3% | 76.5% | |
| flaximum 31-day wait from diagnosis to first definitive treatment for all | 91% to 96% | + | #N/A | #N/A | 100.076 | 30.078 | 100.076 | 00.276 | 00.776 | 100.078 | 00.378 | 100.0 % | 34.176 | 33.376 | 70.576 | \ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| ancers | >=96% | Rank | 1/23 | 1/23 | | | 6/207 | 206/207 | 207/207 | 4/207 | 1 | 6/207 | 185/207 | 191/207 | 195/195 | |
| | <89% | Italik | 100.0% | 100.0% | 100.0% | 96.3% | 0/207 | 100.0% | 100.0% | 100.0% | 100.0% | 83.3% | 100.0% | 100.0% | 83.3% | |
| laximum 31-day wait for subsequent treatment where that treatment is | 89% to 94% | - | #N/A | #N/A | 100.078 | 90.578 | | 100.078 | 100.078 | 100.078 | 100.078 | 03.378 | 100.078 | 100.078 | 03.378 | \ \ |
| urgery | >=94% | Rank | 1/23 | 1/23 | | | _ | 26/207 | 29/207 | 19/207 | 25/207 | 192/207 | 19/207 | 27/207 | 183/195 | |
| | <93% | Nank | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | • |
| Maximum 31-day wait for subsequent treatment where the treatment is | 93% to 98% | - | #N/A | #N/A | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | 100.078 | |
| n anti-cancer drug regimen | >=98% | Rank | 1/23 | 1/23 | | | 35/207 | 38/207 | 40/207 | 36/207 | 40/207 | 41/207 | 39/207 | 38/207 | 1/195 | |
| | >=96% <89% | Rank | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ****** |
| Maximum 31-day wait for subsequent treatment where the treatment is | | - | #N/A | #N/A | 100.076 | 100.076 | 100.076 | 100.0 /6 | 100.0 /6 | 100.0 /8 | 100.0 /6 | 100.0 /6 | 100.076 | 100.076 | 100.076 | |
| course of radiotherapy | 89% to 94% >=94% | Rank | 1/23 | 1/23 | | | 27/207 | 34/207 | 36/207 | 26/207 | 28/207 | 30/207 | 33/207 | 31/207 | 1/195 | |
| | >=94% <80% | Nank | 68.8% | 90.0% | 72.7% | 85.9% | 100.0% | 80.0% | 71.4% | 100.0% | 40.0% | 33.3% | 57.1% | 80.0% | 66.7% | A |
| Maximum 62-day wait from urgent GP referral to first definitive | <80% 80% to 85% | + | #N/A | #N/A | 12.170 | 65.9% | 100.0% | 00.0% | 11.4% | 100.0% | 40.0% | 33.376 | 37.176 | 00.0% | 00.7% | ~ ~ \ \ . |
| reatment for cancer | >=85% | Rank | 23/23 | 1/23 | | | 2/207 | 136/207 | 197/207 | 1/207 | 207/207 | 207/207 | 194/207 | 112/207 | 181/195 | |
| | >=85% <85% | Nank | 100.0% | 100.0% | 66.7% | 100.0% | 2/20/ | 136/207 | 0.0% | 1/201 | 201/201 | 50.0% | 194/207 | 112/207 | 101/195 | |
| Maximum 62-day wait from referral from an NHS screening service to | <85% 85% to 90% | + | #N/A | | 00.7% | 100.0% | | 100.0% | 0.0% | | | 50.0% | | | | · \ • |
| rst definitive treatment for all cancers | >=90% | Rank | #IN/A 1/23 | #N/A 1/23 | | | _ | 20/207 | 194/207 | _ | | 188/207 | | | | • |
| | >=90% | rdilk | 1/23 | 1/23 | 100.0% | 100.0% | - | 100.0% | 194/207 | - | | 100/20/ | 100.0% | | | |
| Maximum 62-day wait for first definitive treatment following a | | + | #N/A | #N/A | 100.0% | 100.0% | | 100.0% | | | | | 100.0% | | | |
| consultants decision to upgrade the priority of the patients (all cancers) | | Rank | #IN/ <i>F</i> A | #IN/A | | | _ | 12/207 | _ | _ | | | 0 | | | L |
| divad Sax Assammadation | | Rank | lup 47 | Jul-17 | Aug 17 | Son 47 | Oct-17 | | Dec-17 | Jan-18 | Feb-18 | Mar-18 | - | May 49 | lun 40 | |
| lixed Sex Accommodation | 40 | | Jun-17 | Jui-17 | Aug-17 | Sep-17 | Oct-T/ | Nov-17 | Dec-17 | Jan-18 | Feb-18 | War-18 | Apr-18 | May-18 | Jun-18 | * |
| and the second of Milliand Court Assessment debtions | >10 | - | | | | | | | | | | | | | 1/195 | \land |
| reaches of Mixed-Sex Accommodation | 1 to 10 | Б. | | | | | 00/22= | | 00/227 | 40/00= | 00/22= | 40/22= | 00/22= | 00/22= | | <i>/ }</i> |
| | 0 | Rank | NA | | | | 20/207 | | 20/207 | 19/207 | 22/207 | 19/207 | 22/207 | 30/207 | | |
| lental Health | | | 14-15 Q4 | 15-16 Q1 | 15-16 Q2 | 15-16 Q3 | 15-16 Q4 | 16-17 Q1 | 16-17 Q2 | 16-17 Q3 | 16-17 Q4 | 17-18 Q1 | 17-18 Q2 | 17-18 Q3 | 18-19 Q1 | |
| Care Programme Approach (CPA): Percentage of people under adult | <90% | | 95.2% | 89.7% | 94.6% | 97.5% | 02.7% | 100.0% | 100.0% | 96.5% | 100.0% | 100.0% | 89.6% | 96.0% | 96.0% | |
| nental illness specialities on CPA who were followed up within 7 days | 90% to 95% | + | 95.2% | 69.7% | 94.6% | 97.5% | 92.7% | 100.0% | 100.0% | 90.5% | 100.0% | 100.0% | 69.6% | 96.0% | 96.0% | V |
| f discharge from psychiatric inpatient care during the period | | D | 47/00 | 00/00 | 40/00 | 40/00 | 04/00 | 4/00 | 4/00 | // NI /A | 4/00 | 7/007 | 400/00= | 405/005 | | |
| alconarge from poyoniatile inpatient date during the period | >=95% | Rank | 17/23 | 23/23 | 19/23 | 12/23 | 21/23 | 1/23 | 1/23 | #N/A | 1/23 | 7/207 | 196/207 | 135/207 | | |

| Dementia | | | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | Jul-18 | |
|---|------------|------------|--------------|--------|--------|---------|---------|---------|---------|---------|---------|---------|--------|--------|-------------|-------------------|
| | <62% | | 81.8% | 82.3% | 81.1% | 80.9% | 83.0% | 82.1% | 81.8% | 86.4% | 83.7% | 82.8% | 82.6% | 83.3% | 83.1% | |
| Dementia diagnosis rate | 62% to 67% | | | | | | | | | | | | | | | ~~~ |
| | >=67% | Rank | | | | 20/207 | | 16/207 | 16/207 | | 9/207 | | 12/207 | | | |
| IAPT Monthly | | | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | |
| | <70% | | 100.0% | 90.9% | 85.7% | 92.9% | 92.9% | 92.9% | 93.3% | 90.9% | 91.7% | 92.9% | 100.0% | 81.8% | 92.9% | |
| IAPT 6 Weeks First Treatment | 70% to 75% | | | | | 0=070 | 0=1070 | | | | | | | 0070 | | 1 |
| | >=75% | Rank | | | | | | | | | | | | | | |
| IADT 40 M In First Transfer and | <90% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.9% | 100.0% | 90.9% | 100.0% | \\\ |
| IAPT 18 Weeks First Treatment | 90% to 95% | D | | | | | | | | | | | | | | |
| IART (Relling Consents) | >=95% | Rank | A 47 | N 47 | 1 47 | 1.1.47 | A 47 | 0 47 | 0.447 | No. 47 | D | Jan. 40 | F.1.40 | M 40 | A 40 | |
| IAPT (Rolling 3 month) | 4.000 | | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | |
| IADT Access (ralling 2 months) | <4.20% | - | 5.0% 4.2% | 5.4% | 5.1% | 4.7% | 4.3% | 4.2% | 4.3% | 4.4% | 4.1% | 3.8% | 3.4% | 3.3% | 3.0% | |
| APT Access (rolling 3 months) | >=4.75% | Rank | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% | |
| | <45% | Nank | | | | | | | | | | | | | | |
| IAPT Recovery rate (rolling 3 months) | 45% to 50% | + | 45.5% | 44.1% | 48.3% | 50.0% | 48.6% | 45.2% | 41.9% | 42.5% | 36.8% | 40.5% | 36.1% | 42.9% | 42.9% | |
| The Process of the Committee of the Process of the | >=50% | Rank | | | | | | | | | | | | | | <u>`</u> |
| Early Intervention Psychosis - 2 Week Waits (rolling quarter) | | - rear inc | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | Jul-18 | |
| ` | <45% | | 75.00/ | 00.00/ | F7.40/ | 00.5% | 07.70/ | 77.00/ | 00.00/ | 00.00/ | 00.70/ | 70.00/ | 74.00/ | 04.00/ | 47 40/ | \wedge \wedge |
| Early intervention in psychosis - 2 week wait (Rolling quarter) | 45% to 50% | | 75.0% | 69.2% | 57.1% | 62.5% | 67.7% | 77.8% | 63.0% | 62.2% | 66.7% | 76.2% | 71.0% | 61.3% | 47.4% | |
| | >=50% | Rank | | | | | 143/207 | 103/207 | | | 142/207 | | | | | |
| Safe Environment and Protecting from Avoidable Harm | | | Jun-17 | Jul-17 | Aug-17 | Sep-17 | Oct-17 | Nov-17 | Dec-17 | Jan-18 | Feb-18 | Mar-18 | Apr-18 | May-18 | Jun-18 | |
| Incidence of healthcare associated infection (HCAI) i) MRSA - Cases which have been assigned to the CCG following a Post Infection | >0 | | 0 | | 1 | | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | | |
| eview | | Rank | 1/23 | | | 132/207 | | 40/207 | 36/207 | 33/207 | 38/207 | 38/207 | 43/207 | 30/207 | 1/195 | |
| ncidence of healthcare associated infection (HCAI) ii) C.difficile | >Ceiling | | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 2 | A A |
| | <=Ceiling | Rank | 1/23 | | | | | 185/207 | 181/207 | 157/207 | | 202/207 | 30/207 | 29/207 | 28/195 | |
| | Ceiling | 22 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 9 | 2 | 2 | 2 | |